F.No. 12(7)/2017/DP/NPPA/Div.II/ Vol-III National Pharmaceutical Pricing Authority

Subject: Minutes of the 13th meeting of Multidisciplinary Committee of Experts held on 24.09.2019 at 11:00 AM in NPPA

13th meeting of the "Multidisciplinary Committee of Experts" was held on 24.09.2019 under the Convenorship of the Sh. Kalyan Nag, Adviser(Cost), in the Conference Room of NPPA. The following members/officers attended the meeting:-

- 1. Dr.C.D.Tripathi, Head Department of Pharmacology, VMMC & Safdarjung Hospital.
- 2. Dr. K. Bangarurajan, Jt. Drugs Controller, CDSCO
- 3. Dr. Rajni Kaul, Scientist-G, ICMR, New Delhi
- 4. Dr. Ujwal Kolhe, Asstt Professor, NIPER, Rae Bareili
- 5. Dr. Gaurav Pratap Singh, Sr. Scientific Officer, Indian Pharmacopoeia Commission
- 6. Shri APS Sawhney, Director (Pricing), NPPA
- 7. Sh. Prasenjit Das, Assistant Director (Pricing), NPPA
- 8. Sh. Prakash Hemani, Assistant Director (Pricing), NPPA

Agenda No. 1 - Retail price fixation under Para 5 of DPCO, 2013 for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Windlas Biotech Pvt. Ltd (manufacturer/ importer)

The Committee deliberated upon the matter in details and recommended the retail price of each hard gelatin capsule containing Atorvastatin Calcium eq to Atorvastatin 40 mg (as pellets) + Clopidogrel Bisulphate IP eq to Clopidogrel 75 mg (as two brown coloured film coated each containing 37.5 mg clopidogrel tablet IP) + Aspirin IP 75 mg (as enteric coated white coloured pellets) for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Windlas Biotech Ltd (manufacturer/importer) at Rs. 12.78 per capsule excluding GST as detailed below:

| Sl. No. | Formulation | Source/ Method | Calculation based on earlier Notified/ Derived Price (ex. GST) | Remarks |
|---------|---|--|---|---|
| a | Each hard gelatin capsule containing Aspirin IP 75 mg +Atorvastatin IP 20 mg + Cloidogrel IP 75 mg | SO. 3982(E) dated 13.08.2018 | Rs 5.22 per capsule | Latest retail price of the formulation fixed for another company |
| b | Derived price of Atorvastatin 20 mg capsule | Pharmatrac data for the month of December 2018 | Rs. 8.60 per capsule | Calculation of price of 10 mg capsule based on para 4 and applying the recommendation of Pronob Sen Committee formulation for deriving the price of 20 mg capsule |
| С | TOTAL (a+b) | description and see | Rs. 13.82 per capsule | |
| d | Less: 20% of the lowest of (a) and (b) similar to formula recommended in the Pronab | | Rs. 1.04 | |

Page 1

| | Sen Committee | |
|----|--------------------------------|-----------------------|
| e | Net derived retail price (c-d) | Rs. 12.78 per |
| f. | Claimed retail price | Rs. 22.00 per |
| g. | Recommended retail price | Rs. 12.78 per capsule |

Agenda No. 2 Retail price fixation under Para 5 of DPCO, 2013 for M/s Cipla Ltd (marketer) and M/s Cipla Ltd (manufacturer/importer).

The Committee deliberated upon the matter in details and recommended the retail price of each capsule (dry powder inhalation) containing Glycopyrronium (as glycopyrrolate USP)25 mcg + Formoterol Fumarate Dihydrate 12 mcg for M/s Cipla Ltd (marketer) and M/s Cipla Ltd (manufacturer/ importer) at Rs. 10.96 per capsule excluding GST as detailed below:

| Sl. No. | Formulation | Source/ Method | Calculation based on earlier Notified/ Derived Price (ex. | Remarks |
|------------|--|---|--|---|
| a | Derived price of Formoterol 12 mcg + Glycopyrrolate 12.5 mcg capsule | Pharmatrac data for the month of January 2019 | Rs. 8.26 per capsule | Calculation based on para 4 of DPCO 2013 |
| b | Derived price of Glycopyrrolate 12.5 mg capsule | Pharmatrac data for the month of January 2019 | Rs. 3.37 per capsule | Calculation of price of 50 mcg capsule based on para 4 and applying the recommendation of Pronob Sen Committee formulation for deriving the price of 12.5 means and |
| С | TOTAL (a+b) | mly contacting | Rs. 11.63 per capsule | the price of 12.5 mcg capsule |
| d | Less: 20% of the lowest of (a) and (b) similar to formula recommended in the Pronab Sen Committee | | Rs. 0.67 | |
| е | Net derived retail price (c-d) | this is | Rs. 10.96 per capsule | |
| f. | Claimed retail price | | Rs. 13.00 per capsule | |
| g. | Recommended retail price | | Rs. 10.96 per capsule | |

Agenda no. 3 Retail price fixation under Para 5 of DPCO, 2013 for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Intas Pharmaceuticals Ltd (manufacturer/ importer)

The Committee noted that M/s Intas Pharmaceuticals Ltd had applied for retail price fixation of each 100 ml infusion containing Levetiracetam IP 500 mg in 0.82% Sodium Chloride and ceiling price notified is of Sodium chloride 0.9% injection. The Committee deliberated upon the matter in details and opined that the difference in sodium chloride content has negligible impact on price. Accordingly, the Committee recommended the retail price of each 100 ml infusion containing Levetiracetam IP 500 mg in 0.82% Sodium Chloride + Water for Injection IP for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Intas Pharmaceuticals Ltd (manufacturer/ importer) at Rs. 98.98 per pack excluding GST as detailed below:

| Sl. | Formulation | Source/ Method | Calculation based | Remarks |
|-----|---|---|--|--|
| No. | | | on earlier Notified/ Derived Price (ex. GST) | |
| a | Derived price Levetiracetam 500 mg injection 5 ml | Pharmatrac data for the month of January 2019 | Rs. 88.15 per pack | Calculation as per para 4 of DPCO 2013 |
| b | Sodium chloride 0.9% injection 100 ml non-glass | S.O. 1485(E) dated 29.03.2019 | Rs. 15.47 per pack | As per form I application, Sodium chloride strength is 0.54%. However due to non availability of data of 0.54% sodium chloride injection, the price of sodium chloride 0.9% injection was taken. |
| С | TOTAL (a+b) | 500 | Rs. 103.62 per pack | |
| d | Less: 30% of the lowest of (a) and (b) similar to formula recommended in the Pronab Sen Committee | | Rs. 4.64 | |
| e | Net derived retail price (c-d) | allah sentuan | Rs. 98.98 per pack | |
| f. | Claimed retail price | engaliger at large | Rs. 200.00 per pack | |
| g. | Recommended retail price | Calmer and Silly | Rs. 98.98 per pack | |

Agenda no. 4 Retail price fixation under Para 5 of DPCO, 2013 for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Intas Pharmaceuticals Ltd (manufacturer/ importer)

The Committee noted that M/s Intas Pharmaceuticals Ltd had applied for retail price fixation of each 100 ml infusion containing Levetiracetam IP 1000 mg in 0.75% Sodium Chloride and ceiling price notified is of Sodium chloride 0.9% injection. The Committee deliberated upon the matter in details and opined that the difference in sodium chloride content has negligible impact on price. Accordingly, the Committee recommended the retail price of each 100 ml infusion containing Levetiracetam IP 1000 mg in 0.75% Sodium Chloride + Water for Injection IP for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Intas Pharmaceuticals Ltd (manufacturer/ importer) at Rs. 160.68 per pack excluding GST as detailed below:

| Sl. No. | Formulation | Source/ Method | Calculation based on earlier Notified/ Derived Price (ex. GST) | Remarks |
|------------|--|---|---|--|
| a | Derived price Levetiracetam 1000 mg injection 5 ml | Pharmatrac data for the month of January 2019 | Rs. 149.85 per pack | Calculation of 500 mg injection as per para 4 of DPCO 2013 and applying the formula of Pronab Sen Committee |
| b | Sodium chloride 0.9% injection 100 ml non-glass | S.O. 1485(E) dated 29.03.2019 | Rs. 15.47 per pack | As per form I application, Sodium chloride strength is 0.54%. However due to non availability of data of 0.54% sodium chloride injection, the price of sodium chloride 0.9% injection was taken. |
| С | TOTAL (a+b) | | Rs. 165.32 per | The state of the s |

1

| d | I and 2007 C. 1 | pack | When the part of the |
|----|---|----------------|----------------------|
| u | Less: 30% of the lowest of (a) and (b) similar to formula recommended in the Pronab Sen Committee | Rs. 4.64 | |
| е | Net derived retail price (c-d) | Rs. 160.68 per | |
| f. | Claimed retail price | Rs. 250.00 per | |
| g. | Recommended retail price | Rs. 160.68 per | |

Agenda no. 5 Retail price fixation under Para 5 of DPCO, 2013 for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Intas Pharmaceuticals Ltd (manufacturer/ importer)

The Committee noted that M/s Intas Pharmaceuticals Ltd had applied for retail price fixation of each 100 ml infusion containing Levetiracetam IP 1500 mg in 0.54% Sodium Chloride and ceiling price notified is of Sodium chloride 0.9% injection. The Committee deliberated upon the matter in details and opined that the difference in sodium chloride content has negligible impact on price. Accordingly, the Committee recommended the retail price of each 100 ml infusion containing Levetiracetam IP 1500 mg in 0.54% Sodium Chloride + Water for Injection IP for M/s Intas Pharmaceuticals Ltd (marketer) and M/s Intas Pharmaceuticals Ltd (manufacturer/ importer) at Rs. 222.39 per pack excluding GST as detailed below:

| Sl. No. | Formulation | Source/ Method | Calculation based on earlier Notified/ Derived Price (ex. GST) | Remarks |
|------------|--|---|---|---|
| a | Derived price Levetiracetam 1500 mg injection 5 ml | Pharmatrac data for the month of January 2019 | Rs. 211.56 per pack | Calculation of 500 mg injection as per para 4 of DPCO 2013 and applying the formula of Pronab Sen Committee |
| b | Sodium chloride 0.9% injection 100 ml non-glass | S.O. 1485(E) dated 29.03.2019 | Rs. 15.47 per pack | As perform I application, Sodium chloride strength is 0.54%. However due to non availability of data of 0.54% sodium chloride injection, the price of sodium chloride 0.9% injection was taken. |
| С | TOTAL (a+b) | | Rs. 227.03 per pack | omoride 0.570 injection was taken. |
| d | Less: 30% of the lowest of (a) and (b) similar to formula recommended in the Pronab Sen Committee | | Rs. 4.64 | |
| e | Net derived retail price (c-d) | | Rs. 222.39 per pack | |
| f. | Claimed retail price | | Rs. 300.00 per pack | early fee in 109 weet p |
| g. | Recommended retail price | | Rs. 222.39 per pack | |



Agenda no. 6 Retail price fixation under Para 5 of DPCO, 2013 for M/s Theon Pharmaceuticals Limited (Manufacturer) and M/s Alkem Laboratories Limited (marketer).

The Committee deliberated upon the matter in details and recommended the retail price of each tablet containing Amoxycillin Trihydrate IP eq. to Amoxycillin 250mg + Dicloxacillin Sodium IP eq. to Dicloxacillin 250mg + Lactic Acid Bacillus 2.5 Billion Spores for M/s Theon Pharmaceuticals Limited (Manufacturer) and M/s Alkem Laboratories Limited (marketer) at Rs. 7.64 per tablet excluding GST as detailed below:

| Computation of Retail Price per Capsule | Source/Method | Amoxycillin 250mg + Dicloxacillin 250mg + Lactic Acid Bacillus 2.5 Billion Spores |
|--|--|---|
| Composition - Amoxycillin 250mg + Dicloxacillin 250mg + Lactic Acid Bacillus 2.5 Billion Spores | | Acid Bacillus 2.3 Billion Spores |
| a. Amoxycillin 250mg + Dicloxacillin 250mg Capsule + Lactic Acid Bacillus 60Million Spores | Retail Price calculated as per Para 4 | 7.31 |
| b. L Lactic Acid Bacillus 2.44 Billion (2.5Billion – 60 Million) Spores | Rs. 0.017/- per 10 Million Spores (SO 2458 (E) 24.09.2009 of DPCO, 1995) for 10 Capsules | 0.41 |
| Worked out Retail Price | | 7.72 |
| c. Less 20% of the lowest of (a) and (b) similar to formula recommended in the Pronab Sen Committee report | | 0.08 |
| Net Retail Price (a+b-c) | | 7.64 |
| Company Claimed Price | | 8.93 |
| Recommended price | | Rs. 7.64 per tablet excluding GST. |

Agenda no. 7 Retail price fixation under Para 5 of DPCO, 2013 for M/s Glenmark Pharmaceuticals Limited (Manufacturer and marketer).

The Committee deliberated upon the matter in details and observed that M/s Glenmark Pharmaceuticals Ltd has submitted a letter to withdraw the Form-I application due to internal business decision. Accordingly, the Committee decided not to recommend the retail price of each film coated tablet containing Remoglifozin Etabonate 100mg + Metformin HCL IP 500mg for M/s Glenmark Pharmaceuticals Limited (Manufacturer and marketer).

Agenda no. 8 Retail price fixation under Para 5 of DPCO, 2013 for M/s Maneesh Pharmaceuticals Limited (Manufacturer and Marketer)

The Committee deliberated upon the matter in details and recommended the retail price of each sachet containing Paracetamol IP 500mg + Phenylephrine HCL IP 10mg M/s Maneesh Pharmaceuticals Limited (Manufacturer and Marketer) at Rs. 2.27 per sachet excluding GST as detailed below:

| Computation of Retail Price per Sachet | Source/Method | |
|--|-------------------------------------|------|
| Composition – Paracetamol 500mg + Phenylephrine HCL 10mg Sachet | | |
| a. Paracetamol 500mg Tablet | Ceiling Price as per SO 1485(E) dt. | 0.89 |

1

| b. Phenylephrine HCL 10mg Tablet * | 29.03.2019 | |
|---|--|-----------------------------|
| Worked out Retail Price | Retail Price calculated as per para 4 (January, 19 data) | 1.18 |
| c. Less 20% of the lowest of (a) and (b) | | 2.07 |
| similar to formula recommended in the Pronab Sen Committee report | | 0.18 |
| d. Additional Packing Material for Sachet | As per Table Below | 0.38 |
| Net Retail Price (a+b-c+d) | | 2.27 |
| Company Claimed Price Recommended price | | 25 |
| recommended price | | Rs. 2.27 per sachet ex. GST |

^{*} The Retail price for Phenylephrine HCL 10mg Tablet has been calculated by calculating price of Phenylephrine HCL 10mg + Chlorpheniramin 4mg Tablet and reducing the retail price of Chlorpheniramin 4mg tablet.

The additional cost of sachet has been calculated as below.

| S.No. | Particulars | |
|----------|--|--------------|
| 1. | Packing Material cost of Sachet (CC PC | Amount (Rs.) |
| 2. | Packing Material cost of Sachet (CC,PC norms of year 2012 under DPCO, 1995) Less: Packing Material for Tablet | Rs. 0.37 |
| 1,12,-2, | (As per above norms) | Rs. 0.05 |
| 3. | Additional Cost (1-2) | |
| 4. | Additional Cost with WPI benefit from 2014-15 to 2018-19 | Rs. 0.32 |
| | 1 raditional cost with wr1 benefit from 2014-15 to 2018-19 | Rs. 0.38 |

Agenda no. 9 Application for grant of separate price/ special price for "Synchrobreathe inhaler device" under the provision of Para 11(3) or para 32(3) of DPCO 2013

The Committee deliberated upon the matter in details and examined the studies/ publications submitted by M/s Cipla Ltd during the course of meeting to substantiate their claim for separate price. The Committee gone through the documents and observed that the clinical studies data shows that the different age groups had substantial reduction in requirement of oral steroids, antibiotics and Beta 2 agonists using this. The Committee also noted that the device result in ease of compliance to children and old age group patients and eliminates requirement of separate spacer. Thus, the Committee is of the opinion that this is an additional advantage as compared to normal inhaler and accordingly recommended that "Synchrobreathe inhaler device" of M/s Cipla Ltd may be separately priced.

Agenda no. 10 Application of M/s Glenmark Pharmaceuticals Ltd for separate price of "Budesonide+ Formeterol MDI Digital Inhalation under the brand "Digihaler"

The Committee deliberated upon the matter in details and noted that NPPA vide letter dated 13.09.2019 has sought suitable guidelines/ modalities from Department of Pharmaceuticals, to be followed for fixation of ceiling/ retail price of innovative drugs when no reference price is available. Accordingly, the Committee decided to defer till response in this regard is received from Department of Pharmaceuticals.

Agenda no. 11 Retail price fixation under Para 5 for M/s Cipla Limited (marketer) and M/s Nanz Med Science Pharma Private Limited (manufacturer)

The Committee deliberated upon the matter in details and recommended to give the ceiling price of Povidone Iodine IP 10% Ointment based on Explanation I to Schedule I of DPCO, 2013.

Agenda no. 12 Retail price fixation under Para 5 of DPCO, 2013 - Darunavir 800 mg and Ritonavir 100 mg tablet for M/s Emcure Pharmaceuticals Ltd (marketer) and M/s Hetero labs Ltd (manufacturer/ importer).

The Committee deliberated upon the matter in details and recommended the retail price of each film coated tablet containing Darunavir Ethanolate eq to Darunavir 800 mg + Ritonavir IP 100 mg for M/s Emcure Pharmaceuticals Ltd (marketer) and M/s Hetero labs Ltd (manufacturer/ importer) at Rs. 197.55 per tablet excluding GST based on the latest PTR as submitted by M/s Hetero Healthcare Ltd in Form-V.

The meeting ended with a vote of thanks to the Convener.

(APS Sawhney) Director (Pricing)

Copy to:

All members of the Committee.

Atorvastatin 10 mg capsule

| Simport of the state of the sta | % Reduction with compared to His | % Reduction with compared to Dichest Dei | | Retail Price (without local taxes) | | Retail Price (without local taxes) | | Add: 16% Retailer Margin Retail Price (without local taxes) | | Average PTR | | Number of Packs considered | | Sum of PTR per unit considered for price calculation | | Sum of MAT value considered for price calculation (in | | Apove | |
|--|----------------------------------|--|------|------------------------------------|------|------------------------------------|--|---|------|---------------------|---|------------------------------|---------------------------------|--|--------------------------|---|--|-------|--|
| HEST FILE | Post Dring | | | | | | | | | r price calculation | | price calculation (in Lakhs) | nine and and art for the second | SAOGH OF TAN ON THE LANDING | DATE OF CHARLES OF TOTAL | | | | |
| | | | | | | | | | | | | | | | | | | | |
| 0.000/ | | 4.78 | 0.00 | 0.66 | 4.12 | | | | 4.12 | | ~ | | | | | | | | |

| 4.78 | Retail Price (Rs.) |
|------|---------------------------------|
| 4.12 | Average of all considered (Rs.) |
| 4.12 | Maximum Price (Rs.) |
| 4.12 | Minimumum Price (RS.) |

| | | 100 | Worked out Retail Price | | | | | A I ORLIP 10 MG CAPSULE 15 | | | | | | acy pesculption | Pack Description | S.No. 40 Iddsal | |
|--|--|--------------------|-------------------------|----------------|---|-------------|------------|----------------------------|-----------|-----------------|---|------------------|-----------------|--------------------|------------------|-----------------|--|
| | | 4.7 | | Rs. per tablet | | | A CONCUE | ATOBIJA | | | | | | BRAND | | शिख | |
| | | 4.78 Excluding GST | | | | | CIPLA LID. | | | | | | Construction | Company | 11 11 | कंपनी | |
| | | | | | | | 10 MG | | | | | | | 0 | Strength | | |
| | | | | | | CT | 15 | | | | | | | . 000 0120 | Pack Size | | |
| | | | | | | CAPSULE | CARCILIE | | | | | | | | | | |
| | | | | | | 61./8 | | | | | | | | TIK (KS.) | DTD (D-) | TOTAL MAT | |
| | | | | | 000000000000000000000000000000000000000 | 86680108 63 | | | | | | | | MAT (Rs.) | | 8.66.80.109 | |
| | The second secon | | | | 100.0070 | 100 00% | | | | | | MAT % | | SKU wise | | 100% | |
| | | | | | 100.00.70 | 100 00% | | | O% MAT) N | (ignoring Y=Yes | 1 | e MAT Y | | Brandwis Qualify (| | | |
| | | | | | - | < | | | | | | | | malify (p | | | |
| | | | | | 4.12 | 200 | | | | (Rs.) | | er Unit (| | rico | CIVI | CM | |
| | | | | | 4.12 | | | | | | 100000000000000000000000000000000000000 | (Rs.) Considered | Line her office | Price per I lait | | | |

Deriving price of 20 mg capsule based on the price of 10 mg capsule in line with the formula prescribed by Pronob Sen Committee P(s)= P* x [1+0.8([S-10]/10]] pP* rice for pack sizes i.e. 20 mg pP* = Price of reference pack size i.e. 10 mg capsule s= pack size whose price is to be determined i.e. 20 mg P(s)=47.78 x [1+0.8([20-10]/10]] Rs. 8.60 per 20 mg capsule excluding GST

GLYCOPYRROLATE 50 mcg capsule

% Reduction with compared to Highest Price Average PTR
Add: 16% Retailer Margin
Retail Price (without local taxes) Number of Companies cosisting of Market Share of 1% & Above
Sum of MAT value considered for price calculation (in Lakhs)
Sum of PTR per unit considered for price calculation
Number of Packs considered 0.00% 9.90 1.58 11.48 9.90

827.70

| Retail Price (Rs.) |
|---------------------------------|
| Average of all considered (Rs.) |
| Maximum Price (Rs.) |
| |

| Strength Pack Size | GLENMARK PHARMACEUTICALS LTD. 50 MCG BE Excluding GST | Company Strength Pack Size U Company GLENMARK PHARMACEUTICALS LTD. 50 MCG 30 18 Excluding GST | Company Strength Pack Size Unit PTR (Rs.) MAT (Rs.) GLENMARK PHARMACEUTICALS LITD. 50 MCG 30 CAPSULE 297.14 82770116.3 | Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT (Rs.) MAT (Rs.) | Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT (Rs.) MAT (Rs.) | Company Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % Sku wise MAT % MAT (Rs.) MAT (Rs.) MAT % MAT % | | vvolked out Retail Price | Worked out Bet I D. | | | | 1 AIRZ DPI 50 MCG CAPSULE 30 | | | Pack Description | S.No. 4th Iddin |
|---|--|---|---|--|--|---|--|--------------------------|---------------------|----------------|------|-------------------------------|------------------------------|------------------|-----------|------------------|-----------------|
| Strength ARMACEUTICALS LTD. 50 MCG | Strength Pack Size U | Strength Pack Size Unit ARMACEUTICALS LTD. 50 MCG 30 CAPSULE | Strength Pack Size Unit PTR (Rs.) MAT (Rs.) | Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % | Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % | Strength Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % | | 11.4 | iva. bei capsule | De por conculo | | - THINE | AIR7 | | | BRAND | छाप |
| 67 | Pack Size U | Pack Size Unit 3 30 CAPSULE | Pack Size Unit PTR (Rs.) MAT (Rs.) 30 CAPSULE 297.14 82770116.3 | Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % 30 CAPSULE 297.14 82770116.3 100.00% | Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % 30 CAPSULE 297.14 82770116.3 100.00% | Pack Size Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % 3 30 CAPSULE 297.14 82770116.3 100.00% | | 8 Excluding GST | | | | GLENMAKK PHARMACEUTICALS LTD. | | | | Company | कंपनी |
| Pack Size | Pack Size Unit 30 CAPSULE | SULE | PTR (Rs.) MAT (Rs.) PTR (Rs.) MAT (Rs.) SULE 297.14 82770116.3 | PTR (Rs.) MAT (Rs.) SKU wise MAT % 927.14 82770116.3 100.00% | PTR (Rs.) MAT (Rs.) SKU wise MAT % 927.14 82770116.3 100.00% | PTR (Rs.) MAT (Rs.) SKU wise MAT % 927.14 82770116.3 100.00% | | | | | | 50 MCG | | | | ou on gui | Strongth |
| | Unit | SULE | PTR (Rs.) MAT (Rs.) PTR (Rs.) MAT (Rs.) SUILE 297.14 82770116.3 | PTR (Rs.) MAT (Rs.) SKU wise MAT % 927.14 82770116.3 100.00% | PTR (Rs.) MAT (Rs.) SKU wise MAT % 927.14 82770116.3 100.00% | PTR (Rs.) MAT (Rs.) SKU wise MAT % 927.14 82770116.3 100.00% | | | | | | 30 | | | | Fack Size | Dank Sina |
| 8.27,70,116 IOW | 70,116 | SKU wise Brandwis Qualify (Price MAT YIN) (gnoring Y=Yes O% MAT) N=No (Rs.) | M3 Brandwis Qualify (Price Price PAT Y/N) per Unit (Rs.) O% MAT) N=No 100.00% Y 9.90 | M3 Walify (Price Print (R.) N) per Unit (R.) = Yes (Rs.) = No Y 9.90 | M3 ice Pr r Unit (R: | | | | | | 9.90 | | | (Ks.) Considered | To be die | Price per Unit | |

Deriving price of 12.5 mcg capsule based on the price of 50 mcg capsule in line with the formula prescribed by Pronob Sen Committee P(s) = P* x [14.08([5.2*]/S*])]
p(S) = Price for pack size is 20mg
p* = Price of reference pack size i.e. 10 mg capsule
s= pack size whose price is to be determined i.e. 20 mg
S*=reference strength
i.e. Rs. 3.37 for 12.5 mcg capsule

FORMOTEROL 12 mcg + GLYCOPYRROLATE 12.5 mcg Sum of MAT \
Sum of PTR pa

| 8.26 | Retail Price (Rs.) |
|------|---------------------------------|
| 7.12 | Average of all considered (Rs.) |
| 7.12 | Maximum Price (Rs.) |
| 7.12 | Minimumum Price (Rs.) |

S.No. पैक विवरण Pack Description

छाप BRAND

कंपनी Company

Strength

Pack Size Unit

PTR (Rs.)

82,38,676 MAT (Rs.)

SKU wise MAT %

Brandwis Qualify (Price e MAT Y/N) Per Unit (Ignoring Y=Yes (Rs.)

Price per Unit (Rs.) Considered

AIRZ F 12/12.5 MCG CAPSULE 30

Worked out Retail Price

Rs. per capsule

GLENMARK PHARMACEUTICALS LTD.

12/12.5 MCG

30

CAPSULE

213.57

8238676.32

100.00%

100.00%

8.26 Excluding GST

| sulation (nakhs) | % Reduction with compared to Highest Price | (widiout local taxes) | Retail Price (without local taxon) | Add: 16% Retailer Margin | Average PTR | acro considered | Number of Packs considered | Sum of PTR per unit considered for price calculation | Saill of IVIA I value considered for price calculation (in Lakhs) | Sum of MAT value considered & |
|------------------|--|-----------------------|------------------------------------|--------------------------|-------------|-----------------|----------------------------|--|---|--|
| | | | | | | | | culation | lation (in Lakhs) | The state of the s |

Levetiracetam 500 mg injection 5ml

| Jum of MAT value considered for price calculation (In Lakhs) Vumber of Packs considered for price calculation Vumber of Packs considered Verage PTR Idd. 16% Retailer Margin ketail Price (without local taxes) 6 Reduction with compared to Highest Price | % Reduction with compared to Highest Price | Retail Price (without local taxes) | Add: 16% Retailer Margin | Number of Packs considered | Sum of PTR per unit considered for price calculation | Sum of MAT value considered for price calculation (in Lakhs) |
|--|--|------------------------------------|--------------------------|----------------------------|--|--|
| | hest Price | | | | r price calculation | price calculation (in Lakhs) |

Minimumum Price (Rs.)

Maximum Price (Rs.)

Average of all considered (Rs.)

Retail Price (Rs.)

54.00 86.02 75.99 88.15

| S.No. पैक विवरण | छाप | कंपनी | 2 | | | TOTAL MAT | 2,81,68,565 | 100% | | | M3 | |
|-------------------------------------|--------------|--|----------|-----------|------|-----------|--|--|--------------|------|-------|------------------|
| Pack Description | BRAND | Company | Strength | Pack Size | Unit | PTR (Rs.) | MAT (Rs.) | SKU wise | Siv | | | Price per Unit |
| | | | | | | | | | (ignoring Y | on | (Rs.) | (Rs.) Considered |
| 1 EDICETAM FOO MC MISCONIA | | | | | | | | | O% MAT) N=No | N=No | | |
| EPICEIAM 500 MG INJECTION 5 ML | EPICETAM | NEON LABORATORIES I TD | 500 MG | 4 | | | | | | | | |
| 2 EPITRA 500 MG INJECTION 5 ML | FPITRA | LIMITY LABORATORIES | O WIND | - | PACK | 54 | 10141779 | 36.00% | 36.00% | ~ | 54.00 | 54.00 |
| 3 KEPPRA 500 MG INJECTION 5 MI | KERRA | The state of the s | DIM MC | 1 | PACK | 86.02 | 4904501.36 | 17.41% | 17.41% | ~ | 86.02 | 86.02 |
| 4 LEVIHOR SOO MG INJECTION 5 M | 700 | UN. REDUTS LABORATORIES LTD | 500 MG | 1 | PACK | 81.78 | 12568414.8 | 44 62% | 44 62% | < | 81 78 | 81 78 |
| THAT CHICAGO INC. INSECTION OF INTE | LEVITOR | ANAX LIFE SCIENCES PVT.LTD | 500 MG | 1 | PACK | 82 14 | 553970.03 | 1 070/ | 4 070/ | < | 000 | |
| | | | | | | | 1 | 44 1011 | | | 04.14 | 02.14 |
| | Rs. Per pack | | | | | | | | | | | |
| Worked out Retail Price | 88 1 | 88 15 Excluding CCT | | | | | | | | | | |
| | 200 | the state of the s | | | | | The second secon | The second secon | | | | 1 |

Deriving price of 1000 mg and 1500 mg injection in line with the formula prescribed by Pronab Sen Committee based on the price of 500 mg injection P(s)= P*x [1+0.7([5.5*)/5*)]
p(S)= Price for pack sizes to be determined p*= Price of reference pack size
s= pack size whose price is to be determined
5*=reference pack/ strength
1000 mg injection=Rs. 149.85 per pack
1500 mg injection=Rs. 149.85 per pack

Each capsule containing Amoxycillin 250mg + Dicloxacillin 250mg + Lactic Acid Bacillus 60M spores for M/s
Theon Pharmaceuticals Limited (manufacturer) and M/s Alkem Laboratories Limited (marketer)

| | r | | _ | _ | , | | , | | _ | | | | | | | | |
|---|-----------------------|--|------|------------------------------------|--|--------------------------|---|-------------|---|-----------------------------------|---------------------------|---|-------------------------|-------------------------|-------------------------|---|---------|
| | and compar | % Reduction with compared to Highort Brice | | Retail Price (without local taxes) | 0 | Add: 16% Retailer Margin | | Average PIR | | THE PROPERTY OF LACKS COLLSIGELED | Number of Backs committee | Sain of Liv bei affit colls | Sum of DTP por unit com | DISUO SIND AGINE COUSIG | Sum of MAT value consid | Number of Companies co | Nin-LCO |
| | ed to tilgilest Price | ed to Highort Brice | | taxes) | | | | | | red | | Jan of Fire Per utilit considered for price calculation | | Calculation (in Lakhs) | | Number of Companies cosisting of Market Share of 1% & Above | |
| | | | | | | | | | | | | | 1 | (in Lakhs) | | 1% & Above | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | The second secon | | | | | | | | | | | | |
| 5 | 40000 | | 7.31 | 1.01 | | 6.30 | | | ω | | 18.90 | | 927.92 | - | L. | | |

| in oposeu retail Frice | Proposed rotal Dailo | Claimed Retail Price | Worked out Retail Price | Walland | | | 250/250/60M CAPSULE 10 | 8 TOF CLON LB 230 MIG/250MIG/60B CAPSULE J TOPCLOX LB | 7 TOPCION IB 350 MG/350MG/80M CAPSULE STARCLUX LB | 6 STARCLOX I B 250 MG/250MG/60M CARCILL | TO ANCHON ID MEM 250 MG/250MG/60M C/NOVACLOX LB | 5 NOVACION IB NICHT SECTION (SOME CAPSULE I MOXIPIL LB | 4 MOYIDII IB DED MC /DEDMC /COM CONTROL | 3 KLOMOX 250 MG/250MG/50M CARCILLE 10 VIOLON | E BAXIN D LB PLUS 250 MG/250MG/60M CAPS BAXIN D LB PLUS | 2 BAYIN DID 200 1816/ 2301816/ BOIN CAPSULE IL BACNIL LB | 1 BACNII IB 250 MG/250MG/50M CARSHIE | Pack Description |
|------------------------|----------------------|----------------------|-------------------------|------------------|-------------|----------------------------|-------------------------|---|---|---|---|--|---|--|--|--|--------------------------------------|------------------|
| 7.31 | - | | 7.31 | (Rs. Per tablet) | | | TRESMOXIBD | J TOPCLOX LB | E STARCLOX LB | Total Control | NOVACLOX LB | IMOXIPIL LB | VECINION | KIONOV | S BAXIN D LB PLUS | LUBACNIL LB | DRAND | ple |
| 7.31 Excluding GST | Excluding GST | 6 | 7.31 Excluding GST | | | ADDOTT TEALTHCAKE PVT. LID | ABBOTT HEALTHCARE SIZE | PSYCHOTROPICS INDIA LTD | INVISION MEDI SCIENCES | 10000 | CIPIAITO | PSYCHOTROPICS INDIA LTD | LINCOLN PHARMACEUTICALS LTD | THE PROPERTY OF LED | HETERO HEALTHCARE LTD | CHEM + MED PHARMACEUTICALS | Company | कंपनी |
| | | | | | | 250/250/60M | GOO / DIAIOCZ / DIAIOCZ | 250MG/350MG/60B | 250MG/250MG/60M | 250MG/250MG/60M | and control control | 250MG/250MG/60M | 250MG/250MG/60M | 250MG/250MG/60M | MINO VOINIO TO MINO TO | 250MG/250MG/60M | | Strength |
| | | | | | | 10 | TO | 10 | 10 | 10 | TO | 10 | 10 | 10 | TO | 1 | | Pack Size |
| | | | | | 00000 | CAPSIIIF | CAPSULE | CAPSULE | CARCUIT | CAPCILLE | CAPSULE | CAPSOLE | CARCILLE | CAPSUIF | CAPSULE | | Citi | - Inii |
| | | | | | 10.04 | 75 04 | 30.7 | 0.1 | 37.00 | 20 63 | 25.6 | 56.07 | 10.70 | 46.43 | 48.98 | | rin (ns.) | DTD (D) |
| | | | | | /64319//.58 | 76476476 | 408983 | 38.2 | 13614458 | 40044450 | 443429.3 | 2745858.24 | 1.77017 | 21822 1 | 277921.71 | | MAI (RS.) | 9,39,44,488 |
| | | | | | 81.36% | 04.000 | 0 44% | 0.00% | 14.49% | | 0.47% | 2.92% | 0.0270 | 0000 | 0.30% | 0/ I WIM | SKU wise | |
| | | | | | 81.36% | 0,44,0 | 7000 | 0.00% | 14.49% | | 0.47% | 2.92% | 0.02% | | 0.30% | e MAI | S | 6 |
| | | | | | ~ | 2 | 2 | z | ~ | | z | ~ | z | | Z | Y/N) | | |
| | | | | | 7.50 | 3.07 | 202 | 0.01 | 5.79 | 1.00 | 2.56 | 5.61 | 4.64 | 1.00 | 4 90 | per Unit (| _ | M3 |
| | | | | | 7.50 | | | | 5.79 | | | 5.61 | | | | (Rs.) Considered | Price per Unit | |

| 7.3 | Retail Price (Rs.) |
|------|---------------------------------|
| 6.3 | Average of all considered (Rs.) |
| 7.50 | Maximum Price (RS.) |
| 5.6 | |

Each tablet containing Phenylephrine HCL 10mg + Chlorpheniramin 4mg

Number of Companies cosisting of Market Share of 1% & Above
Sum of MAT value considered for price calculation (in Lakhs)
Sum of PTR per unit considered for price calculation
Number of Packs considered

43.33

| | | | - | | | | | | |
|--------------------------------|---------------------|-----------------------|--------|------|------|------|---|------|-----|
| | | | | | | | | | |
| Average of all considered (Dr. | Maximum Price (Rs.) | Minimumum Price (Rs.) | | | | | | | |
| dorod (Br.) | - | (Rs.) | | | | | | | |
| | | | | | | | | | |
| | 1 | 1 | 24.75% | 1.73 | 0.24 | 1.49 | 2 | 2.98 | 10. |

| Proposed retail Price | Claimed Retail Price | VVOIRED OUT RETAIL PRICE | Work of the state | | | 2 MAXTRA 4/10 MG TABLET 10 | DIOMINIC DC 10/4 MG TABLET 10 | Pack Description | S.No. पैक विवरण | | | | | | | | | |
|-----------------------|----------------------|--------------------------|--|------------|-------------------------|----------------------------|-------------------------------|--------------------------|-----------------|--------------------|---------------------------------|---------------------|-----------------------|--------|--|------------------------------------|--------------------------|--------------------|
| 1.73 | 1 | 1.73 | (INS. FEI IIII) | (Re Darmi) | | MAXTRA | DIOMINIC DC | ND | p163 | | | | | | | | | |
| 1.73 Excluding GST | Excluding GST | 1.73 Excluding GST | | | COVENIOS HEALINCARE LID | ZIIVENTIIS HEAITHCABE LTD | UNISON PHARMACEUTICALS | Company | कंपनी | | | | | | | | | |
| | | | | | 4/10 MG | DIAI +/OT | 10/4 MG | Strength | | | | | | | % Reduction with compared to Highest Price | Retail Price (Without local taxes) | Aud. 10% Retailer Margin | A 44 . 160/ Dotail |
| | | | | | 10 | 10 | 3 | Pack Size | | | | | | | compared to Hi | out local taxes) | r Margin | |
| | | | The second secon | | TABLET | IABLEI | | Unit | | | | | | 0 | ighest Price | | | |
| | | | | | 19.75 | 10 | | PTR (Rs.) | TOTAL MAT | | | | | | | | | |
| | | | | | 3669884.5 | 663224.73 | | MAT (Rs.) | 43,33,109 | | | | | | | | | |
| | | | | | 84.69% | 15.31% | | SKU wise | 100% | Retail Price (Rs.) | Average of all considered (Rs.) | Maximum Price (Rs.) | Minimumum Price (Rs.) | | | | | |
| | | | | | 84.69% | 15.31% | 1 | Brandwis Qualify (Price | | | nsidered (Rs.) | (Rs.) | ice (Rs.) | | | | | |
| | | | | | ~ | ~ | (N/1 | ualify (| | | | | | | | | | |
| | | | | | 1.98 | 1.00 | per unit | | M3 | | | | | | | | | |
| | | | | | 1.98 | 1.00 | (Ks.) Considered | Price per Unit | | 1.73 | 1.49 | 1.98 | 1.00 | 24./5% | | 1.73 | 0.24 | 1.43 |

S.No. पैक विवरण Pack Description

Each tablet containing Chlorpheniramin 4mg

| % neduction with compared to Highest Price | OV Double to the second | Retail Price (without local taxes) | Total Mail Mail | Add: 16% Retailer Margin | Average PIR | 749 | Number of Packs considered | Sum of PTR per unit considered for price calculation | or MAI value considered for price calculation (in Lakhs) | Number of Companies cosisting of Market Share of 1% & Above |
|--|--|------------------------------------|-----------------|--------------------------|-------------|-----|----------------------------|--|--|---|
| | | | | | | | | | | Ve . |

| Claimed Retail Price Proposed retail Price | rice | | | SUCCESSION STANDARD IN STANDARD TOOL | | CHLURPHENIRAMINE 4 MG TABLET 10 | CHLORPHENIRAMINE (AGRON) 4 MG TABLET | - ace pescripaton | |
|--|----------------------------------|-------------|-----------|--------------------------------------|-------------------------------|---------------------------------|---|--------------------|-----------|
| Excluding GST 0.55 Excluding GST | (NS. Her ml) 0.55 Excluding GST | (Do Dosell) | | CHLORPHENIRAMINI MENARINI INDIA | SI TONI MINIMI MENAKINI INDIA | CHI ORPHENIBAMINI MENADINI MICH | CHLORPHENIRAMINE (AGRON) 4 MG TABLET CHLORPHENIRAMINI AGRON REMEDIES PVT. LTD | BRAND Company | छाप कंपनी |
| | | | 1 1410 | 4 MG | 4 MG | A IVIG | 440 | 9 | Strength |
| | | | T000 | 1000 | 10 | 1000 | | ack olse | Dack City |
| | | | IABLEI | IMPLEI | TABLET | TABLET | | Ollif | |
| | | | 58.22 | 13 | 3 | 44.68 | | PIK (Rs.) | TOTAL MAT |
| | | | 200550.99 | 897 | 100000 | 49996 97 | | MAT (Rs.) | 2,51,445 |
| | | | 79.76% | 0.36% | 10.00% | 10 88% | MAT % | SKU wise | 100% |
| | | | 80.12% | 80.12% | 13.0070 | 1 | e MAT | Brandwis Qualify (| 01 |
| | | | < | ~ | 1 | - | Y/N) | Qualify (| |
| | | 0.00 | 30.0 | 1.30 | 0.04 | 1 | | (Price I | Ma |
| | | 0.00 | 200 | 1.30 | 0.04 | | (Rs.) Considered | Price per Unit | |

| Retail Price (Rs.) |
|---------------------------------|
| |
| Average of all considered (Rs.) |
| |
| Maximum Price (Rs.) |
| |
| The (No.) |

1.18

| 0.47 | Average of all considered (Rs.) |
|------|---------------------------------|
| 1.30 | Maximum Price (Rs.) |
| 0.04 | IVIIIIImumum Price (Ks.) |

| 63.85% |
|--------|
| |

|--|--|--|